SCHEMBL936610

SCHEMBL936610

CCN(C=O)N(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12651664 0.83 ALDH1A1 (0.38)
SCHEMBL6110192 0.79
SCHEMBL572460 0.77
SCHEMBL5235261 0.73 ADH1C (0.36)
SCHEMBL27689613 0.69
SCHEMBL4579062 0.69
SCHEMBL23229179 0.69
SCHEMBL28829 0.67
SCHEMBL5522835 0.67
Dimethylformamide SCHEMBL28338245 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4636486-B2 2011-02-23 JP claimed
US-20080227828-A1 Aryl Ureas With Angiogenisis Inhibiting Activity BAYER HEALTHCARE LLC 2008-09-18 US claimed
EP-1478358-A1 ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY Bayer Pharmaceuticals Corporation (US) 2004-11-24 EP claimed
US-20030207870-A1 Aryl ureas with angiogenisis inhibiting activity BAYER CORPORATION 2003-11-06 US claimed
WO-2003068228-A1 ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY BAYER PHARMACEUTICALS CORPORATION (US) 2003-08-21 WO claimed
WO-2000044216-A2 GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS CYTOVIA INC (US) 2000-08-03 WO claimed
EP-0078478-B1 HIGH-FREQUENCY WELDABLE POLYURETHANE FOAMS, AND PROCESS FOR PREPARING THE SAME BAYER AG (DE) 1986-05-21 EP claimed
US-10653684-B2 Aryl ureas with angiogenisis inhibiting activity BAYER HEALTHCARE LLC (US) 2020-05-19 US disclosed
US-20180296541-A9 ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY BAYER HEALTHCARE LLC (US) 2018-10-18 US disclosed
US-20160015697-A1 ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY BAYER HEALTHCARE LLC (US) 2016-01-21 US disclosed
US-8618141-B2 Aryl ureas with angiogenesis inhibiting activity BAYER HEALTHCARE LLC (US) 2013-12-31 US disclosed
US-20120289552-A1 ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY BAYER HEALTHCARE LLC (US) 2012-11-15 US disclosed
US-8242147-B2 Aryl ureas with angiogenisis inhibiting activity BAYER HEALTHCARE LLC (US) 2012-08-14 US disclosed
US-20030216396-A1 Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors BAYER CORPORATION 2003-11-20 US disclosed
US-20030207870-A1 Aryl ureas with angiogenisis inhibiting activity BAYER CORPORATION 2003-11-06 US disclosed
WO-2003068229-A1 PYRIDINE, QUINOLINE, AND ISOQUINOLINE N-OXIDES AS KINASE INHIBITORS BAYER PHARMACEUTICALS CORPORATION (US) 2003-08-21 WO disclosed
WO-2003068228-A1 ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY BAYER PHARMACEUTICALS CORPORATION (US) 2003-08-21 WO disclosed
WO-2000044216-A2 GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS CYTOVIA INC (US) 2000-08-03 WO disclosed
CN-1050122-C Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them KRAL THOMAE GMBH (DE) 2000-03-08 CN disclosed
CN-1083812-A Benzimidazoles contains the pharmaceutical composition of these compounds and their preparation KRAL THOMAE GMBH (DE) 1994-03-16 CN disclosed